Eden Research plc Appointment of Global Product and Marketing Lead

RNS Number : 6664W

Eden Research plc

17 July 2024

 

17 July 2024

 

 

Eden Research Plc

("Eden" or "Company")

 

Appointment of Global Product and Marketing Lead

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and a plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, is delighted to announce the appointment of Daniel Mulas García as the Company's new Global Product and Marketing Leader with immediate effect.

 

Daniel has extensive experience in sustainable crop protection, most recently working as Product Manager, Biostimulants and Biocontrol for Sipcam Iberia, an important commercial partner of Eden, for close to ten years.  During his time with Sipcam, Daniel was responsible for the launch and management of many innovative crop protection and nutrition products, including playing a critical role in the success of Eden's Araw® biofungicide across the region. A key aspect of his role at Sipcam was to understand future trends in agriculture and regulation in order to address the needs of farmers by staying in close contact with key customers, influencers and policy makers to secure the full potential of the products within the portfolio.

 

Daniel holds a Master's degree in Agronomical Engineering and a PhD in Agronomy from the Universidad de León. He will play a significant role as part of Eden's commercial team to help ensure that Eden's current and future products are well-aligned with the needs of farmers in an ever-changing regulatory and commercial environment. Daniel will also help the team to maximise revenue growth through the pursuit of ongoing expansions of the Company's product portfolio.

 

Sean Smith, Chief Executive Officer of Eden Research, commented:

 

"We are pleased to welcome Daniel to the Eden team after many years of working very successfully with him and his colleagues at Sipcam Iberia. Daniel's appointment will not only help to strengthen our product and market knowledge, but also to expand our social media presence and use of new tools to identify and pursue emerging opportunities associated with regulatory change in our industry. Daniel's appointment is a further demonstration of our strong intent to add to our team's commercial capabilities, supported by our stronger balance sheet following last Summer's fundraise and our increasing revenue as we continue to grow the company organically across various fronts. We look forward to Daniel's contributions and the opportunities that lie ahead."

 

For further information contact:

 

Eden Research plc
Sean Smith Alex Abrey	www.edenresearch.com 01285 359 555
Cavendish Capital Markets Limited (Nominated advisor and broker)
Giles Balleny / George Lawson (corporate finance) Charlie Combe (corporate broking) Michael Johnson (sales)	020 7220 0500
Hawthorn Advisors (Financial PR)
Victoria Ainsworth	[e-mail]

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.  It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally.  Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's seed treatment product, Ecovelex was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, U.S. and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine^® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

For more information about Eden, please visit:  www.edenresearch.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NRABQLLFZDLZBBK